ArriVent BioPharma Reports Full Year 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rebounds, but yield surge sets stage for weekly losses
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Oppenheimer Reiterates Outperform Rating on ArriVent BioPharma (AVBP)
March 3, 2025 1:39 PM ESTOppenheimer analyst Jeff Jones reiterated an Outperform rating and $39.00 price target on ArriVent BioPharma (NASDAQ: AVBP).
The analyst comments "On Monday morning, ArriVent BioPharma provided a business update across its pipeline, highlighting progress in 2024, and including year-end financial results. Key updates for AVBP's... More
